$KTRA News
Last published 2y ago
- 2y agoKTRAKintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024PR NewswireKintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA BiosciencesPR NewswireKintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024PR NewswireKintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024PR NewswireKintara Therapeutics, Inc. ("Kintara") (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate UpdatePR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAKintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024PR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA BiosciencesPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, is ...
- 2y agoKTRAKintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical StudyPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.PR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara") a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRAKATuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerPR NewswireTuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to...
- 2y agoKTRAKATuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorPR NewswireTuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to...
- 2y agoKTRAKintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term MilestonesPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
- 2y agoKTRATuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)PR NewswireTuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to...
- 2y agoKTRAKintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAABIOSWAVNSKuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoKTRAKintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label...
- 2y agoKTRAKintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAKintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdatePR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAKintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAKintara Therapeutics Announces Review of Strategic AlternativesPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAKintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 2y agoKTRAKintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdatePR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 3y agoKTRAKintara Therapeutics Announces Preliminary Topline Results From GBM AGILE StudyPR NewswireKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor...
- 3y agoKTRAKintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth ConferencePR NewswireSAN DIEGO, Oct. 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the LD Micro Main Event XVI ConferencePR NewswireSAN DIEGO, Oct. 2, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual MeetingPR NewswireSAN DIEGO, Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today
- 3y agoKTRAKintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate UpdatePR NewswireSAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual MeetingPR NewswireSAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023PR NewswireSAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the Emerging Growth ConferencePR NewswireSAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.PR NewswireSAN DIEGO, July 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001PR NewswireSAN DIEGO, June 28, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Participate in the Maxim Group Virtual Healthcare ConferencePR NewswireSAN DIEGO, June 16, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor SocietyPR NewswireSAN DIEGO, May 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate UpdatePR NewswireSAN DIEGO, May 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the Sidoti Micro-Cap Virtual ConferencePR NewswireSAN DIEGO, May 8, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the Aegis Capital Virtual ConferencePR NewswireSAN DIEGO, May 1, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual MeetingPR NewswireSAN DIEGO, April 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual MeetingPR NewswireSAN DIEGO, March 15, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023PR Newswire-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO, March 10, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA)
- 3y agoKTRAKintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate UpdatePR NewswireSAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the 2023 BIO CEO & Investor ConferencePR NewswireSAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023PR NewswireSAN DIEGO, Jan. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)PR NewswireSAN DIEGO, Dec. 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022PR NewswireSAN DIEGO, Dec. 1, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireSAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast CancerPR NewswireSAN DIEGO, Nov. 28, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 3y agoKTRAKintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual MeetingPR NewswireSAN DIEGO, Nov. 18, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 4y agoKTRAKintara Announces One-for-Fifty Reverse Stock SplitPR NewswireSAN DIEGO, Nov. 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,
- 4y agoKTRAKintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate UpdatePR NewswireSAN DIEGO, Nov. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,